Evotec Results Presentation Deck
evotec
میرا
PAGE 32
Strong year ahead
Guidance 2021
Very good top-line growth expected
Assumption based on current orders, prospective milestone payments
• Total Group revenues € 550-570 m (€ 565-585 m at constant exchange rates¹))
EBITDA guidance confirmed - despite massive investments
Expanding scope of strategic investments for promising R&D projects, ramp-up of Just -
Evotec Biologics business, expansion of J.PODⓇ 1 US capacities in US & J.POD® 2 EU
Adjusted Group EBITDA²) € 105-120 m (€ 115-130 m at constant exchange rates ¹))
Accelerated R&D investments for growth
• Further expand long-term & sustainable pipeline of first-in-class projects & platforms
Unpartnered Group R&D expenses of € 50-60 m³)
¹) $/ € 2020: 1.15; €/GBP 2020: 1.13
2) Before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result
3) Evotec focuses its guidance and upcoming reporting on the "unpartnered R&D" part. ID-related R&D expenses will be fully reimbursed its partner Sanofi ("partnered R&D").View entire presentation